TG Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for TGTX, updated each market day.
TGTX AI Sentiment
AI predicts TG Therapeutics, Inc. stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.
Sector
Exchange
Market Cap
$5,530,004,305
Cap Tier
Employees
399
Headquarters
NEW YORK, NY
Listed Since
Dec. 14, 1995
Website
TGTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TGTX Volatility
TG Therapeutics, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
